JP2015528469A - 前立腺の治療のための薬物送達システム及び方法 - Google Patents
前立腺の治療のための薬物送達システム及び方法 Download PDFInfo
- Publication number
- JP2015528469A JP2015528469A JP2015530139A JP2015530139A JP2015528469A JP 2015528469 A JP2015528469 A JP 2015528469A JP 2015530139 A JP2015530139 A JP 2015530139A JP 2015530139 A JP2015530139 A JP 2015530139A JP 2015528469 A JP2015528469 A JP 2015528469A
- Authority
- JP
- Japan
- Prior art keywords
- bladder
- gemcitabine
- drug
- patient
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002307 prostate Anatomy 0.000 title claims abstract description 42
- 238000012377 drug delivery Methods 0.000 title claims abstract description 29
- 238000000034 method Methods 0.000 title claims abstract description 22
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 161
- 229940079593 drug Drugs 0.000 claims abstract description 132
- 210000002700 urine Anatomy 0.000 claims abstract description 21
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 11
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 10
- 230000002459 sustained effect Effects 0.000 claims abstract description 8
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 77
- 229960005277 gemcitabine Drugs 0.000 claims description 77
- 239000000463 material Substances 0.000 claims description 27
- 239000011248 coating agent Substances 0.000 claims description 20
- 238000000576 coating method Methods 0.000 claims description 20
- 229940124597 therapeutic agent Drugs 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 210000003708 urethra Anatomy 0.000 claims description 10
- 238000011200 topical administration Methods 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 230000002485 urinary effect Effects 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 5
- 230000037431 insertion Effects 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000003232 mucoadhesive effect Effects 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 239000002254 cytotoxic agent Substances 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims 1
- 201000007094 prostatitis Diseases 0.000 abstract description 3
- 230000014759 maintenance of location Effects 0.000 description 17
- 230000010412 perfusion Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 7
- 239000003826 tablet Substances 0.000 description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 239000013583 drug formulation Substances 0.000 description 4
- 229960001756 oxaliplatin Drugs 0.000 description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- -1 etc.) Polymers 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 235000012434 pretzels Nutrition 0.000 description 2
- 210000005267 prostate cell Anatomy 0.000 description 2
- 208000017497 prostate disease Diseases 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 1
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000003903 pelvic floor Anatomy 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/04—General characteristics of the apparatus implanted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1085—Bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/16—Male reproductive, genital organs
- A61M2210/166—Prostate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nanotechnology (AREA)
- Saccharide Compounds (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、参照により本明細書に組み込まれる、2012年8月31日出願の米国仮特許出願第61/696,029号の利益を主張するものである。
Claims (26)
- ゲムシタビンを含む薬剤であって、前立腺内で薬物の治療濃度を生じさせるために十分な、膀胱内の尿中の薬物の持続的な濃度を達成するように、患者の膀胱内に前記ゲムシタビンを局所的に投与することによる前立腺の治療に使用するための薬剤であり、
前記患者の膀胱への前記局所的投与が、1mg/日〜約300mg/日の前記ゲムシタビン平均量においてなされる、薬剤。 - 前記患者の膀胱内への前記局所的投与が継続的である、請求項1に記載の薬剤。
- 前記患者の膀胱内への前記局所的投与が、少なくとも2時間の期間にわたって継続的である、請求項2に記載の薬剤。
- 前記患者の膀胱内への前記局所的投与が間欠的である、請求項1に記載の薬剤。
- 前記患者が前立腺癌の治療を必要とする、請求項1に記載の薬剤。
- 前記ゲムシタビンが、持続期間にわたって前記膀胱内の前記尿中に前記ゲムシタビンを継続的に放出する膀胱内薬物送達デバイスから、前記膀胱内に送達される、請求項1に記載の薬剤。
- 前記膀胱内薬物送達デバイスが、少なくとも2時間の期間にわたって、前記膀胱内の前記尿中に前記ゲムシタビンを継続的に放出する、請求項6に記載の薬剤。
- 前記膀胱内薬物送達デバイスが、1日〜14日間の期間にわたって、前記膀胱内の前記尿中に前記ゲムシタビンを継続的に放出する、請求項6に記載の薬剤。
- 前記膀胱内薬物送達デバイスが、前記薬物を収容して制御可能に放出する筺体を備え、かつ前記デバイスを患者の膀胱内に保持するように構成される保持形状と、前記患者の尿道を通る前記デバイスの通過のための配置形状と、の間で、弾性的に変形可能である、請求項6に記載の薬剤。
- 前記筺体に収容される前記薬物が、非液体形態である、請求項9に記載の薬剤。
- 前記非液体形態が、錠剤、顆粒剤、半固体剤、カプセル剤、及びそれらの組み合わせから成る群から選択される、請求項10に記載の薬剤。
- 前記薬物が、前記膀胱に塗布されるコーティング物質から前記膀胱内に送達され、前記コーティング物質は、持続期間にわたって、前記膀胱内の前記尿中に前記ゲムシタビンを放出する、請求項1に記載の薬剤。
- 前記コーティング物質が粘膜付着性製剤を含む、請求項12に記載の薬剤。
- 前記局所的投与が、前記膀胱内に配置される尿道カテーテルを通じて、前記膀胱内に前記ゲムシタビンの液体形態をポンピングすることを含む、請求項1に記載の薬剤。
- 前記患者の膀胱内への前記局所的投与が、最大7日間にわたって、1mg/日〜100mg/日の前記ゲムシタビンの範囲である、請求項1〜14のいずれか一項に記載の薬剤。
- 前記患者の膀胱内への前記局所的投与が、最大7日間にわたって、20mg/日〜300mg/日の前記ゲムシタビンの範囲である、請求項1〜14のいずれか一項に記載の薬剤。
- 前記薬物送達デバイスが前記膀胱内に挿入されると前記ゲムシタビンを放出するように構成される、請求項1〜16のいずれか一項に記載の薬剤を含む、薬物送達デバイス。
- 前立腺の治療を必要とする患者に薬物を投与する方法であって、
前立腺内でゲムシタビンの治療濃度を生じさせるために十分な、膀胱内の尿中の前記ゲムシタビンの持続的な濃度を達成するように、患者の膀胱内に局所的にゲムシタビンを投与することを含む、方法。 - 少なくとも第2の治療薬を前記患者に投与することをさらに含む、請求項18に記載の方法。
- 前記第2の治療薬が膀胱内に投与される、請求項19に記載の方法。
- 前記第2の治療薬が、細胞毒性剤、鎮痛剤、抗炎症剤、又はそれらの組み合わせを含む、請求項19又は20に記載の方法。
- 膀胱内挿入のために構成される筺体と、
ゲムシタビンを含む投薬形態と、を備える、医療デバイスであって、
前記筺体が、前記投薬形態を保持し、前立腺の治療に対する治療有効量で、前記膀胱内に前記ゲムシタビンを放出するように構成され、
前記デバイスが、ゲムシタビンを、1mg/日〜約300mg/日の前記ゲムシタビン平均量で、前記膀胱内に放出するように構成される、医療デバイス。 - 前記筺体に収容される前記ゲムシタビンが、非液体形態である、請求項22に記載のデバイス。
- 前記筺体が、前記デバイスを患者の膀胱内に保持するように構成される保持形状と、前記患者の尿道を通る前記デバイスの通過のための配置形状と、の間で、弾性的に変形可能である、請求項22に記載のデバイス。
- 最大7日間にわたって、1mg/日〜100mg/日の前記ゲムシタビンを放出するように構成される、請求項22〜24のいずれか一項に記載のデバイス。
- 最大7日間にわたって、20mg/日〜300mg/日の前記ゲムシタビンを放出するように構成される、請求項22〜24のいずれか一項に記載のデバイス。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261696029P | 2012-08-31 | 2012-08-31 | |
US61/696,029 | 2012-08-31 | ||
PCT/US2013/057841 WO2014036556A2 (en) | 2012-08-31 | 2013-09-03 | Drug delivery systems and methods for treatment of prostate |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015528469A true JP2015528469A (ja) | 2015-09-28 |
JP6309009B2 JP6309009B2 (ja) | 2018-04-11 |
Family
ID=49162284
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015530139A Expired - Fee Related JP6309009B2 (ja) | 2012-08-31 | 2013-09-03 | 前立腺の治療のための薬物送達システム及び方法 |
Country Status (14)
Country | Link |
---|---|
US (2) | US9636488B2 (ja) |
EP (1) | EP2890386A2 (ja) |
JP (1) | JP6309009B2 (ja) |
KR (2) | KR102383496B1 (ja) |
CN (2) | CN112516154A (ja) |
AU (1) | AU2013308465B2 (ja) |
BR (1) | BR112015004110A2 (ja) |
CA (1) | CA2882575C (ja) |
IL (1) | IL237300B (ja) |
IN (1) | IN2015DN01560A (ja) |
MX (1) | MX367070B (ja) |
RU (1) | RU2678308C2 (ja) |
SG (1) | SG11201501483XA (ja) |
WO (1) | WO2014036556A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020528895A (ja) * | 2017-07-25 | 2020-10-01 | タリス バイオメディカル エルエルシー | 腫瘍転移を処置する方法 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015003836A2 (pt) | 2012-08-31 | 2017-07-04 | Taris Biomedical Llc | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga |
SG11201501483XA (en) | 2012-08-31 | 2015-03-30 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine |
WO2015026813A1 (en) | 2013-08-19 | 2015-02-26 | Taris Biomedical Llc | Multi-unit drug delivery devices and methods |
MX2016011333A (es) * | 2014-03-06 | 2016-12-07 | Taris Biomedical Llc | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. |
EP3200801B1 (en) * | 2014-10-02 | 2024-04-24 | University of Maryland, Baltimore | Methods of treating pancreatic cancer |
RS64032B1 (sr) | 2016-05-06 | 2023-04-28 | Taris Biomedical Llc | Metoda lečenja urotelnog raka donjeg trakta |
WO2019094517A1 (en) | 2017-11-08 | 2019-05-16 | Taris Biomedical Llc | Methods of treatment and maintenance therapy for bladder cancer using gemcitabine |
CN112839653A (zh) | 2018-08-01 | 2021-05-25 | 塔里斯生物医药公司 | 使用曲司氯铵治疗膀胱过度活动症的方法 |
US20220107320A1 (en) | 2019-02-15 | 2022-04-07 | Incelldx, Inc. | Assaying Bladder-Associated Samples, Identifying and Treating Bladder-Associated Neoplasia, and Kits for Use Therein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012106714A1 (en) * | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled release of low solubility drug |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6171298B1 (en) | 1996-05-03 | 2001-01-09 | Situs Corporation | Intravesical infuser |
US20040260272A1 (en) | 2002-10-22 | 2004-12-23 | Friedman Craig D. | Method and system for intravesicular delivery of therapeutic agents |
US8361490B2 (en) * | 2004-09-16 | 2013-01-29 | Theracoat Ltd. | Biocompatible drug delivery apparatus and methods |
DE102005020314A1 (de) * | 2005-05-02 | 2006-11-09 | Infineon Technologies Ag | Spannungsversorgungsanordnung zur Versorgung einer ersten elektrischen Last und Verfahren zum Bereitstellen einer elektrischen Leistung |
ES2400091T3 (es) | 2005-08-11 | 2013-04-05 | Massachusetts Institute Of Technology | Dispositivo de suministro de fármacos intravesical y método |
US20100137239A1 (en) | 2006-04-24 | 2010-06-03 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
EP1913962A1 (en) * | 2006-10-22 | 2008-04-23 | Ophir Perelson | Expandable medical device for the treatment and prevention of cardiovascular diseases |
CN101616671A (zh) * | 2007-01-19 | 2009-12-30 | 卫材R&D管理有限公司 | 胰腺癌治疗用组合物 |
CN101896221B (zh) | 2007-12-11 | 2013-06-05 | 麻省理工学院 | 用于治疗膀胱和其它体囊或体腔的可植入式药物递送设备和方法 |
MX2010010635A (es) | 2008-04-04 | 2010-12-17 | Lipella Pharmaceuticals Inc | Tratamiento de la disfuncion de la vejiga usando toxina botulinum liposomal. |
CA2946195A1 (en) * | 2008-07-17 | 2010-01-21 | Micell Technologies, Inc. | Drug delivery medical device |
KR101689786B1 (ko) | 2008-08-09 | 2016-12-26 | 메사츄세츠 인스티튜트 어브 테크놀로지 | 남성 비뇨생식기 및 주위 조직을 치료하는 방법 및 체내이식형 약물 전달 장치 |
CN102470237A (zh) | 2009-06-26 | 2012-05-23 | 塔里斯生物医药公司 | 用于可植入药物递送装置的固体药物片剂 |
US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
PL2512581T3 (pl) | 2009-12-17 | 2021-11-02 | Taris Biomedical Llc | Wszczepiane urządzenie z tolerancją wewnątrzpęcherzową |
WO2011089604A2 (en) | 2010-01-20 | 2011-07-28 | Theracoat Ltd | Material and method for treating internal cavities |
US20110218488A1 (en) | 2010-03-05 | 2011-09-08 | Taris Biomedical, Inc. | Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites |
HUE052160T2 (hu) | 2010-08-05 | 2021-04-28 | Taris Biomedical Llc | Ureterális sztent eszköz gyógyszerbejuttatáshoz és ahhoz való készlet |
US9457176B2 (en) | 2010-10-06 | 2016-10-04 | Taris Biomedical Llc | Implantable drug delivery device with bladder retention feature |
US8690840B2 (en) | 2010-10-06 | 2014-04-08 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
US8979797B2 (en) | 2010-12-16 | 2015-03-17 | Ams Research Corporation | High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics |
WO2012096985A1 (en) | 2011-01-10 | 2012-07-19 | Taris Biomedical, Inc. | Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding |
US20150005595A1 (en) | 2011-12-30 | 2015-01-01 | Kibur Medical, Inc. | Implantable devices and methods for evaluation of active agents |
WO2013170069A1 (en) | 2012-05-09 | 2013-11-14 | Massachusetts Institute Of Technology | Medicament, method, and drug delivery device for treatment of ovarian cancer |
SG11201501483XA (en) | 2012-08-31 | 2015-03-30 | Taris Biomedical Llc | Drug delivery systems and methods for treatment of prostate disease comprising gemicitabine |
BR112015003836A2 (pt) | 2012-08-31 | 2017-07-04 | Taris Biomedical Llc | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga |
EP2897616A1 (en) | 2012-09-18 | 2015-07-29 | TARIS Biomedical LLC | Drug delivery systems and methods for treatment of bladder voiding dysfunction!and other lower urinary tract disorders by using trospium |
CN105163794B (zh) | 2013-03-15 | 2020-03-27 | 塔里斯生物医药公司 | 具有药物可渗透部件的药物递送装置和方法 |
KR102270363B1 (ko) | 2013-03-15 | 2021-06-29 | 타리스 바이오메디컬 엘엘씨 | 약물 전달 장치 |
JP6431528B2 (ja) | 2013-04-10 | 2018-11-28 | マサチューセッツ インスチテュート オブ テクノロジーMassachusetts Institute Of Technology | 癌治療のための薬物局所送達装置及び方法 |
WO2015026813A1 (en) | 2013-08-19 | 2015-02-26 | Taris Biomedical Llc | Multi-unit drug delivery devices and methods |
MX2016011333A (es) | 2014-03-06 | 2016-12-07 | Taris Biomedical Llc | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. |
-
2013
- 2013-09-03 SG SG11201501483XA patent/SG11201501483XA/en unknown
- 2013-09-03 KR KR1020207029566A patent/KR102383496B1/ko active IP Right Grant
- 2013-09-03 AU AU2013308465A patent/AU2013308465B2/en not_active Ceased
- 2013-09-03 MX MX2015002452A patent/MX367070B/es active IP Right Grant
- 2013-09-03 RU RU2015109298A patent/RU2678308C2/ru active
- 2013-09-03 KR KR20157007350A patent/KR20150043508A/ko active Application Filing
- 2013-09-03 CN CN202011468367.8A patent/CN112516154A/zh active Pending
- 2013-09-03 WO PCT/US2013/057841 patent/WO2014036556A2/en active Application Filing
- 2013-09-03 BR BR112015004110A patent/BR112015004110A2/pt not_active Application Discontinuation
- 2013-09-03 CA CA2882575A patent/CA2882575C/en active Active
- 2013-09-03 JP JP2015530139A patent/JP6309009B2/ja not_active Expired - Fee Related
- 2013-09-03 CN CN201380044809.8A patent/CN104812395A/zh active Pending
- 2013-09-03 EP EP13760226.4A patent/EP2890386A2/en active Pending
-
2015
- 2015-02-18 IL IL237300A patent/IL237300B/en active IP Right Grant
- 2015-02-23 US US14/628,874 patent/US9636488B2/en active Active
- 2015-02-25 IN IN1560DEN2015 patent/IN2015DN01560A/en unknown
-
2017
- 2017-03-29 US US15/473,437 patent/US10406335B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012106714A1 (en) * | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled release of low solubility drug |
Non-Patent Citations (1)
Title |
---|
CORONAUER,M.V. ET AL.: ""Inhibitory Effects of the Nucleoside Analogue Gemcitabine on Prostatic Carcinoma Cells"", PROSTATE, vol. 28, no. 3, JPN6017011715, March 1996 (1996-03-01), pages 172 - 181, XP055088360, ISSN: 0003532839, DOI: The Prostate 28: 172-1 8 I ( 1996) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020528895A (ja) * | 2017-07-25 | 2020-10-01 | タリス バイオメディカル エルエルシー | 腫瘍転移を処置する方法 |
JP7391009B2 (ja) | 2017-07-25 | 2023-12-04 | タリス バイオメディカル エルエルシー | 腫瘍転移を処置する方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2882575C (en) | 2020-05-26 |
MX2015002452A (es) | 2015-06-05 |
EP2890386A2 (en) | 2015-07-08 |
US20150165177A1 (en) | 2015-06-18 |
CN104812395A (zh) | 2015-07-29 |
JP6309009B2 (ja) | 2018-04-11 |
CN112516154A (zh) | 2021-03-19 |
BR112015004110A2 (pt) | 2017-07-04 |
US9636488B2 (en) | 2017-05-02 |
WO2014036556A2 (en) | 2014-03-06 |
WO2014036556A3 (en) | 2014-04-17 |
US20170203085A1 (en) | 2017-07-20 |
CA2882575A1 (en) | 2014-03-06 |
KR20150043508A (ko) | 2015-04-22 |
SG11201501483XA (en) | 2015-03-30 |
MX367070B (es) | 2019-08-05 |
KR102383496B1 (ko) | 2022-04-08 |
IN2015DN01560A (ja) | 2015-07-03 |
IL237300A0 (en) | 2015-04-30 |
AU2013308465A1 (en) | 2015-03-05 |
US10406335B2 (en) | 2019-09-10 |
IL237300B (en) | 2020-02-27 |
RU2678308C2 (ru) | 2019-01-25 |
KR20200120774A (ko) | 2020-10-21 |
AU2013308465B2 (en) | 2018-05-17 |
RU2015109298A (ru) | 2016-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10406335B2 (en) | Drug delivery systems and methods for treatment of prostate | |
US11007355B2 (en) | Drug delivery devices and methods for treatment of bladder cancer with oxaliplatin | |
JP7383681B2 (ja) | 薬物送達システム及びゲムシタビンによる膀胱がんの治療方法 | |
JP6600256B2 (ja) | トロスピウムの使用による膀胱排尿機能障害及び他の下部尿路疾患の治療のための薬物送達システム及び方法 | |
NZ723303B2 (en) | Drug delivery systems and methods for treatment of bladder cancer with gemcitabine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160722 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170704 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180301 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180313 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6309009 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |